▎药明康德内容团队编辑今日，阿斯利康（AstraZeneca）公司公布了在研口服GLP-1疗法AZD5004，在患有2型糖尿病的肥胖患者中进行的1期临床试验的最新结果。数据显示，这款在研疗法在治疗4周后将患者体重减轻5.8%，并且改善患者的血糖指标。

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...

2024年11月4日，阿斯利康在在美国圣安东尼奥举行美国肥胖周(ObesityWeek)上，披露了口服小分子 GLP-1 激动剂AZD5004的最新研究进展。 AZD5004（ECC5004 ...

Follow KT on WhatsApp Channels. The results from the trial gave AstraZeneca confidence to progress the drug into Phase II ...

阿斯利康的口服药片“AZD5004”使患者在四周内平均减重5.8%且耐受性良好。分析指出，他们的产品有望与礼来和诺和诺德等公司的畅销注射剂竞争 ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004 ...

After AstraZeneca (AZN) presented data at the ObesityWeek conference, Deutsche Bank said the company’s oral small molecule GLP1 drug ...

Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price ...

当地时间（11月4日），英国阿斯利康公司在美国“肥胖症周”（ObesityWeek）会议上报告了其口服小分子减肥药物的研究数据。 报告显示，在一项早期 ...